(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
6 Useful Home Espresso Machines - 2Apollo vs. Artemis: What to know about NASA's return to the moon
- 3Figure out How to Acquire Rewarding Open Record Rewards
- 4Figuring out the Justification for Separation: To blame and No-Shortcoming
- 5IDF begins destroying homes used by Hezbollah as forces move deeper into southern Lebanon
- Asia's Noteworthy Destinations: A Voyager's Aide
- 6 Arranging Administrations to Change Your Open air Space
- The Specialty of Cleaning up: Change Your Space and Brain
- Grasping the Commencement of Criminal Cases: An Extensive Outline
- Don't fall for it: These common tourist scams in Rome are easy to avoid if you know what you're looking for
- Popular Japanese Hotel Chain Now Lets You Show Up With Just Your Passport
- Artemis 2 breaks humanity's all-time distance record during historic loop around the moon (video)
- The Best Games Crossroads in History
- Vote in favor of the Web-based Work out schedule to Keep You Fit and Sound
